TRAIL treatment was also shown to enhance pro-inflammatory cytokine and chemokine production, including IL6, IL8, MCP1, CXCL1, and MIF, in various cancer cell types independent from TRAIL sensitivity although cytokines levels were higher in resistant cancer cells. This evidence concerns the gene IL6 and cancer.